Hereditary angioedema

Press Releases

FDA press release - new treatment for hereditary angioedema

The U.S. Food and Drug Administration (FDA) has recently approved Cinryze, Berinert and Kalbitor in the United States to protect people with hereditary angioedema (HAE). Click on the links above to read the FDA press releases related to these medications.

Last updated on 04-27-20

Name: US Hereditary Angioedema Association, Inc. Seven Waterfront Plaza 500 Ala Moana Blvd., Suite 400
Honolulu, HI, 96813, United States
Phone: 866-798-5598 Email: info@haea.org Url: http://www.haea.org
Name: HAEi – International Patient Organization for C1 Inhibitor Deficiencies HAEi Kirstinelundsvej 7 DK-8660 Skanderborg
Denmark
Email: info@haei.org Url: http://haei.org/hae/what-is-hae/

Note, these links are external searches against the National Laboratory of Medicine's drug database. You may need to adjust the search if there are no results found.

Drug Name Generic Name
Takhzyro lanadelumab-flyo
Cinryze(R) C1 esterase inhibitor (human)
Haegarda C1-esterase-inhibitor, human, pasteurized

Connect with other users with Hereditary angioedema on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App